Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Opsens Inc T.OPS

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that can be integrated into other medical devices. The Industrial segment develops, manufactures and installs fiber optic sensing solutions for critical and demanding industrial applications. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and lesions access. It is approved for sale in the United States, European Union, Japan and Canada.


TSX:OPS - Post by User

Comment by CriticalCareon Mar 25, 2022 2:27pm
136 Views
Post# 34546412

RE:RE:510k updates?

RE:RE:510k updates? Timelines from FDA are defined and FDA have goals to review their 510k application.

The 60 days to review the dossier and provide questions to the sponsor. https://www.fda.gov/medical-devices/premarket-notification-510k/510k-submission-process

At this time there are 2 options, interactive review when the questions are easy and noncomplex to answer,  they don't put the submission on hold they do meeting with the company and discuss the clarification they need easy and fast process. Or they put your submission on hold for additional information request Company has 180 days to provide info. Seriously if you don't provide the answer within the first 2 months after the AI request, get rid of your clinical/development/regulatory team  . but in these 2 options, they have to send you the first set of questions within 60 days. this means that base on the last PR, The 60 days is now reached and they were put on hold to respond to the Additional information request. I just think that if they do not disclose this information  and that's their right, 

Than why do they do a PR wto state that they filled a 510k if they don't have any intention to keep their investors informed about the current process. 

HC is has totally different product classification (class IV for such  device) and it is way longer than a FDA 510k review process 120 days is correct. Also HC is absolutly miserable on their delay since the Covid ERA they do not have any coordination within the different branch and teams. That's a shame. 

If everything goes well for OPS. (And believe me, I fully thrust and have a great respect for (LL) and the Mgnt team). we should have news within the next 5-6 weeks, (when basic questions or clarification requested) if it goes over 6 weeks, this means that they received safety concerns questions link to potential risk and or they identified a clinical study flaws (ex. Stats or study design) that were not correctly addressed within the 510k submission. 

Now it's a time to buy this stock for all the reason that you already know and you may have a good surprise in few weeks. Let's see the posivite side of it. 
<< Previous
Bullboard Posts
Next >>